SCHEMBL16507920

SCHEMBL16507920

CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 8/20 0.51
PCSK6 P29122 1/20 0.51
NMT2 O60551 1/20 0.50
NMT1 P30419 1/20 0.50
SIRT6 Q8N6T7 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
F2 P00734 1/20 0.47
F10 P00742 1/20 0.47
HPN P05981 1/20 0.47
HGFAC Q04756 1/20 0.47
ST14 Q9Y5Y6 1/20 0.47
SIRT5 Q9NXA8 1/20 0.44
TLR2 O60603 1/20 0.44
KISS1R Q969F8 1/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16234712 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16259360 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16234694 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16259323 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16234693 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16234715 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL16259340 0.95 NMT2 (0.53) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL20951745 0.92 FURIN (0.52) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL20951744 0.92 FURIN (0.52) FURINPCSK6NMT2NMT1SIRT6
SCHEMBL20965523 0.92 SIRT6 (0.52) FURINPCSK6NMT2NMT1SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS ANTHOR THERAPEUTICS, INC. 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS PTH1R, MC1R, CASR FURIN 2446/4885PCSK6 2445/4885NMT2 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.